A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study

Trial Profile

A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Ferric pyrophosphate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CRUISE-1
  • Sponsors Rockwell Medical Technologies
  • Most Recent Events

    • 28 Jun 2017 According to a Rockwell Medical India media release, data from the study will be presented in an oral presentation at the 12th Annual Conference on Nephrology & Urology 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 15 Jul 2015 Results published in Nephrology Dialysis Transplantation (NDT) as per Rockwell Medical, Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top